Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 29, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Real-World Practice Patterns in Diagnosis and First-Line Treatment in Metastatic Breast Cancer.

Poorni M Manohar1, Veena Shankaran2, Nancy E Davidson2

  • 1Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA, rush.edu.

The Breast Journal
|June 28, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
Same author

Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.

Blood neoplasia·2026
Same author

Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy.

Cancers·2026
Same author

Patient- and Physician-Identified Considerations for Clinical Implementation of a New Risk-Based Prediction Tool to Guide Surveillance Mammography in Breast Cancer Survivors.

JCO oncology practice·2026
Same author

Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.

International journal of radiation oncology, biology, physics·2026
Same author

Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2).

NPJ breast cancer·2026

Quality of care for metastatic breast cancer (MBC) varies. Many patients with recurrent MBC did not receive biopsy or biomarker reassessment, impacting treatment choices and potentially leading to suboptimal care. Further initiatives are needed.

Area of Science:

  • Oncology
  • Public Health
  • Health Services Research

Background:

  • Metastatic breast cancer (MBC) care quality is inconsistent, with practice variations affecting patient outcomes.
  • Assessing real-world diagnostic and treatment patterns in MBC is crucial for identifying care gaps.

Purpose of the Study:

  • To evaluate the quality of care for patients with metastatic breast cancer (MBC) in Washington State.
  • To identify disparities in diagnosis and treatment for real-world MBC patients.

Main Methods:

  • Retrospective analysis of linked cancer registry and insurance claims data from 2008-2019.
  • Inclusion of patients with recurrent or de novo MBC.

Main Results:

  • Less than half of recurrent MBC patients received biopsy (49.5%) or biomarker reassessment (48.7%).
Keywords:
CDK4/6 inhibitorsbiopsymetastatic breast cancerquality of caretreatment patterns

More Related Videos

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Related Experiment Videos

Last Updated: Jun 29, 2026

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

  • Higher volume centers showed improved biopsy rates.
  • Treatment patterns, including endocrine therapy (ET) alone versus combination therapies like CDK4/6 inhibitors plus ET (CDKi+ET), varied based on diagnostic procedures and patient insurance.

    • Conclusions:

    • Significant gaps exist in MBC diagnosis and management, particularly regarding biopsy and biomarker testing.
    • Findings underscore the need for quality improvement initiatives to enhance patient-centered MBC care.
    • Variations in treatment, such as the use of ET alone, highlight areas for potential intervention.